Latigo Biotherapeutics Commences IPO Process For Pain Treatment Pipeline

Latigo Biotherapeutics is advancing a pipeline of non-opioid pain treatments, with lead candidate LTG-001 showing promising Phase 2 efficacy and no dependency signals. LTGO is targeting a large, growing non-opioid pain market projected to exceed $70 billion by 2030, driven by aging demographics and R&D investment. The company is well-capitalized with $302 million raised from top-tier life science investors, but will require substantial further funding as it progresses three programs through clinical trials. I expect significant institutional IPO demand, with valuation at IPO likely signaling investor appetite for quality biopharma assets in the $250 million to $500 million enterprise value range.